Compare CBIO & FCRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CBIO | FCRS |
|---|---|---|
| Founded | 2003 | 2025 |
| Country | United States | United States |
| Employees | 44 | N/A |
| Industry | | Blank Checks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.4M | 361.2M |
| IPO Year | N/A | N/A |
| Metric | CBIO | FCRS |
|---|---|---|
| Price | $11.18 | $10.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $26.67 | N/A |
| AVG Volume (30 Days) | 162.2K | ★ 188.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.72 | $10.03 |
| 52 Week High | $17.39 | $10.92 |
| Indicator | CBIO | FCRS |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 36.82 |
| Support Level | $10.45 | N/A |
| Resistance Level | $13.37 | $10.34 |
| Average True Range (ATR) | 0.94 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 20.03 | 21.43 |
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
FutureCrest Acquisition Corp is a blank check company.